Curesponse

Rehovot, Israel Founded: 2018 • Age: 8 yrs
Provider of a tissue culture system to analyze cancer growth and drug response
Request Access

About Curesponse

Curesponse is a company based in Rehovot (Israel) founded in 2018 by Guy Neev, Nancy Gavert, and Ravid Straussman.. Curesponse has raised $14 million across 2 funding rounds from investors including aMoon and NCL. Curesponse offers products and services including cResponse™. Curesponse operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.

  • Headquarter Rehovot, Israel
  • Founders Guy Neev, Nancy Gavert, Ravid Straussman
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $14 M (USD)

    in 2 rounds

  • Latest Funding Round
    $8 M (USD), Series B

    Nov 15, 2021

  • Investors
    aMoon

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Curesponse

Curesponse offers a comprehensive portfolio of products and services, including cResponse™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Evaluates cancer therapies on biopsies for accurate treatment predictions

People of Curesponse
Headcount 10-50
Employee Profiles 7
Board Members and Advisors 8
Employee Profiles
People
Gil Rosen
COO
People
Adi Zundelevich
Genomics Project Manager
People
Guy Neev
Co-Founder & CEO
People
Seth Salpeter
Co-Founder & CTO

Unlock access to complete

Board Members and Advisors
people
Sascha Oliver Bucher
Advisor
people
Jonathan Krell
Advisor
people
Raanan Berger
Advisor
people
Zvika Slovin
Chair, Board of Directors

Unlock access to complete

Funding Insights of Curesponse

Curesponse has successfully raised a total of $14M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $8 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $8.0M
  • First Round

    (05 Jun 2020)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2021 Amount Series B - Curesponse Valuation

investors

Jun, 2020 Amount Series A - Curesponse Valuation aMoon , NCL
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Curesponse

Curesponse has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include aMoon and NCL. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Venture capital investments in healthcare are focused on by aMoon.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Curesponse

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Curesponse

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Curesponse Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Curesponse

Curesponse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Developer of cell-free DNA testing for oncology, women’s health, and organ health
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Molecular cancer diagnostic products are developed using patented AMP technology.
domain founded_year HQ Location
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Curesponse

When was Curesponse founded?

Curesponse was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Curesponse located?

Curesponse is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.

Who is the current CEO of Curesponse?

Guy Neev is the current CEO of Curesponse. They have also founded this company.

Is Curesponse a funded company?

Curesponse is a funded company, having raised a total of $14M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Jun 05, 2020.

What does Curesponse do?

Founded in 2018 in Rehovot, Israel, Curesponse operates in the biotechnology sector, focusing on oncology. A proprietary tissue culture system is utilized to preserve cancer tissue, including vasculature and immune components, for studying tumor behavior in vivo. The cResponse test is offered, evaluating patient tumor samples from biopsies or surgeries against various treatments. This is integrated with genomic analysis to tailor therapies for individual cancer patients.

Who are the top competitors of Curesponse?

Curesponse's top competitors include Guardant Health, Strand Life Sciences and Sutro Biopharma.

What products or services does Curesponse offer?

Curesponse offers cResponse™.

Who are Curesponse's investors?

Curesponse has 2 investors. Key investors include aMoon, and NCL.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available